Public Release: 

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Elastography and serum makers show promise in some patients

Wiley

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

Epidemiological studies report that approximately 150,000 individuals in the U.S. are diagnosed with chronic liver disease each year, and nearly 20% of these cases have cirrhosis at initial presentation. Complications from cirrhosis are determined by the extent and progression of fibrosis or scaring of the liver. Liver fibrosis, however, is not a linear process, but one that fluctuates with the influences of age, sex, race, alcohol exposure and obesity.

Liver biopsy remains the gold standard for determining activity and stage of fibrosis. However, this procedure has inherent limitations that include risk of pain or bleeding, inaccurate staging from sampling error, and variability of biopsy interpretation. With the increase in availability of sophisticated laboratory blood testing, the use of diagnostic liver biopsy is on the decline. "The drawbacks to liver biopsy have prompted researchers to investigate alternative, noninvasive markers for determining the severity of liver disease," said Dr. Jayant Talwalkar of the Mayo Clinic in Rochester, MN and editorial co-author.

Noninvasive screening with serum markers, or indicators in the blood, can identify patients at risk for liver fibrosis. Fibrotest, an indirect serum marker panel, is the most widely used and validated serum marker panel used worldwide. A number of studies have confirmed this panel to be reliable in detecting stage 4 fibrosis (cirrhosis) in patients with chronic HCV. Additional studies are underway to analyze its viability in hepatitis B, alcoholic liver disease, and nonalcoholic fatty liver disease.

Imaging techniques such as ultrasound-based transient elastography (TE) and magnetic resonance elastography (MRE) are noninvasive procedures that measure liver stiffness. Prior studies have found TE to be up to 90% accurate in diagnosing cirrhosis, and 70%-80% accurate in detecting stage 2 to stage 4 fibrosis. Evaluations of MRE have shown up to 85% accuracy for detecting intermediate to severe fibrosis (F2-F4). Currently only MRE is approved for use in the U.S.

"Noninvasive diagnostics are more advantageous to the patient as there are no serious side effects and they may be more cost effective when compared to liver biopsy although this remains to be determined," Dr. Talwalkar concluded. "Fibrotest or elastography imaging are helpful to confirm cirrhosis or minimal to no fibrosis. Liver biopsy may still be necessary to determine stage of fibrosis in those patients where noninvasive techniques were indeterminate."

###

This study is published in Hepatology. Media wishing to receive a PDF of the article may contact healthnews@wiley.com.

Full citation: Editorial: "Noninvasive Assessment of Liver Fibrosis." Doris Nguyen and Jayant A. Talwalkar. Hepatology; Published Online: May 25, 2011 (DOI: 10.1002/hep.24401); Print Issue Date: June 2011. http://onlinelibrary.wiley.com/doi/10.1002/hep.24401/abstract

About the Journal

Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1527-3350 .

About Wiley-Blackwell

Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.